<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, the potential negative role of <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> drugs is under intensive investigation </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the effects of treatment with <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> or insulin on the extension of left ventricular myocardial dysfunction induced by <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Nineteen consecutive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> entered the study </plain></SENT>
<SENT sid="3" pm="."><plain>Each patient was randomly assigned to either insulin or <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment was crossed over after 12 weeks and maintained for another 12 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>At the end of each treatment, left ventricular myocardial function at rest and during <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> infusion was studied by two-dimensional echocardiography under the same conditions of metabolic control </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi> or insulin treatment did not influence the rest values of left ventricular dimensions, left ventricular ejection fraction (LVEF), or wall motion score index (WMSI) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="4653">Dipyridamole</z:chebi> infusion, in patients receiving <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> treatment, decreased LVEF (43 +/- 7 vs. 37 +/- 12%, P &lt; 0.005) and increased WMSI (1.4 +/- 0.28 vs. 1.98 +/- 0.24, P &lt; 0.001) compared with baseline values; during insulin treatment, LVEF (46 +/- 8 vs. 45 +/- 11%, NS) and WMSI (1.4 +/- 0.29 vs. 1.6 +/- 0.4, NS) did not change significantly </plain></SENT>
<SENT sid="8" pm="."><plain>Peak stress LVEF was higher (45 +/- 11 vs. 37 +/- 12%, P &lt; 0.001) and WMSI lower (1.6 +/- 0.4 vs. 1.98 +/- 0.24, P &lt; 0.001) in patients receiving insulin </plain></SENT>
<SENT sid="9" pm="."><plain>The results indicate that in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, <z:e sem="disease" ids="C0349780" disease_type="Disease or Syndrome" abbrv="">ischemic myocardial dysfunction</z:e> induced by <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> infusion is less severe during treatment with insulin than with <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Restitution of a preconditioning mechanism in insulin-treated patients may be the potential beneficial mechanism </plain></SENT>
</text></document>